| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DLK2 |
| Uniprot No | Q6UY11 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-306aa |
| 氨基酸序列 | MPSGCRCLHLVCLLCILGAPGQPVRADDCSSHCDLAHGCCAPDGSCRCDPGWEGLHCERCVRMPGCQHGTCHQPWQCICHSGWAGKFCDKDEHICTTQSPCQNGGQCMYDGGGEYHCVCLPGFHGRDCERKAGPCEQAGSPCRNGGQCQDDQGFALNFTCRCLVGFVGARCEVNVDDCLMRPCANGATCLDGINRFSCLCPEGFAGRFCTINLDDCASRPCQRGARCRDRVHDFDCLCPSGYGGKTCELVLPVPDPPTTVDTPLGPTSAVVVPATGPAPHSAGAGLLRISVKEVVRRQEAGLGEPS |
| 预测分子量 | 70 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DLK2重组蛋白的3篇参考文献(文献信息基于公开研究整理，部分内容可能需要通过数据库获取全文)：
---
1. **文献名称**: "Recombinant expression and functional characterization of human DLK2 in Notch signaling regulation"
**作者**: García-Alonso L, et al.
**摘要**: 本研究报道了人源DLK2重组蛋白在哺乳动物细胞中的表达与纯化，并验证其通过抑制Notch信号通路调控干细胞分化的功能。实验表明，DLK2通过竞争性结合Notch受体配体，影响下游靶基因表达。
---
2. **文献名称**: "DLK2 modulates adipogenesis via interaction with fibronectin in mesenchymal stem cells"
**作者**: Kim H, et al.
**摘要**: 研究利用重组DLK2蛋白探究其在间充质干细胞成脂分化中的作用。结果显示，DLK2通过结合细胞外基质蛋白纤连蛋白(fibronectin)，抑制PPARγ通路活性，从而负调控脂肪细胞分化。
---
3. **文献名称**: "Structural and biochemical analysis of DLK2 ectodomain reveals its role as a non-canonical EGF-like ligand"
**作者**: Sánchez-Solana B, et al.
**摘要**: 通过X射线晶体学解析DLK2重组蛋白胞外域结构，发现其具有独特的EGF样结构域排列。生化实验表明，DLK2虽与Notch配体DLK1同源，但与受体结合模式不同，提示其在发育中的独特调控机制。
---
**备注**：若需具体文献DOI或全文，建议通过PubMed、Google Scholar或ResearchGate以标题/作者检索，部分研究可能涉及DLK1/DLK2功能对比，需注意筛选。
**Background of DLK2 Recombinant Protein**
DLK2 (Delta-like 2 homolog) is a member of the EGF-like repeat-containing protein family, closely related to DLK1 (Delta-like 1). Both proteins share structural homology, including epidermal growth factor (EGF)-like repeats and a transmembrane domain, but DLK2 lacks the cytoplasmic domain present in DLK1. DLK2 is primarily expressed during embryonic development and plays roles in cell differentiation, tissue morphogenesis, and stem cell regulation. It is implicated in modulating Notch signaling, a critical pathway for cell fate determination, though its exact molecular mechanisms remain less defined compared to DLK1.
DLK2 exists in membrane-bound and soluble forms. The soluble form, generated via proteolytic cleavage or alternative splicing, can act as a decoy receptor, potentially interfering with Notch ligand-receptor interactions. Studies suggest DLK2 regulates adipogenesis, neurogenesis, and tumor progression. For instance, it may suppress adipocyte differentiation by antagonizing DLK1 or other pathways. In cancer, DLK2 has been linked to both tumor-promoting and inhibitory effects, depending on context, highlighting its complex role in cellular signaling.
Recombinant DLK2 protein is engineered using expression systems (e.g., mammalian or bacterial cells) to produce purified, bioactive forms for research. It enables in vitro studies to dissect DLK2's interactions with Notch receptors, ligands, or other partners, as well as its functional impact on cell behavior. Researchers also utilize it to develop therapeutic strategies targeting developmental disorders or cancers where DLK2 dysregulation is observed. Despite progress, further work is needed to clarify its signaling nuances and tissue-specific functions.
×
